Sign in
Taking people in United StatesNo phase

Blood Samples Collected to Study a Blood Test for Cancer

Collects blood from healthy adults and people with cancer or liver disease.

Key facts

Who runs it
Helio Genomics
Where
Coon Rapids, Dallas, Fridley, Memphis, Minneapolis, Redondo Beach, and Richardson, United StatesSee the 7 sites
Trial code
Registry title
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
Status
Recruiting
People taking part
1,200 people, planned
Started
21 May 2019
Expected to end
Jan 2028
Type of study
Observational
Treatments tested
  • Multi-analyte Blood Test
Record updated
10 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with cancer, cancer in remission, a benign (non-cancer) disease, or healthy volunteers. Blood samples are collected for research on blood tests.

Age
18 years or older
Sex
All sexes can join
Disease stage
Cancer, cancer in remission, or a benign disease such as benign tumor, diabetes, liver cirrhosis, chronic hepatitis B or C, or COPD. Healthy volunteers can also join.

Main reasons for not taking part

  • Cannot sign the informed consent form
  • Already gave 50 mL of blood in the last 8 weeks

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • 2.1.1 Age 18 years or older
  • 2.1.2 A diagnosis of cancer, cancer remission, benign disease (benign tumor, diabetes, liver cirrhosis, chronic hepatitis B or hepatitis C virus infection, Chronic obstructive pulmonary disease, etc.) or apparently healthy volunteers.

Who cannot take part

  • 2.2.1 Patients that are unwilling or unable to sign the Informed Consent Form will be excluded
  • 2.2.2 Approximately 50 mL of blood will be drawn from participants within an 8-week period under this protocol. Patients that have already given 50 mL of blood within this time frame will be excluded

Where in United States

  • Allina Health, Virginia Piper Cancer InstituteCoon Rapids, United StatesContact: Kathryn GruetzmanTaking people
  • Liver Center of TexasDallas, United StatesContact: Ariela MorenoTaking people
  • Virginia Piper Cancer Institute Mercy Hospital-Unity CampusFridley, United StatesContact: Lynne SchroederTaking people
  • Methodist LeBonheur HealthcareMemphis, United StatesContact: Carol JonesTaking people
  • VPCI Oncology ResearchMinneapolis, United StatesContact: Kelsey FroemmingTaking people
  • Torrance Memorial Physician Network - Cancer CareRedondo Beach, United StatesContact: Clinical Operations ManagerNo longer taking part
  • Methodist HospitalRichardson, United StatesContact: Araceli TorresTaking people

About the trial

What the trial wants to find out

To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign conditions that may induce false positive or false negative results, and iii) defining the effects of potential interfering substances, such as chemotherapy drugs.

Treatments tested

  • Multi-analyte Blood Test

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
Plain-language title
Blood Samples Collected to Study a Blood Test for CancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
10 July 2026